Vericel (VCEL) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. QGEN
10. KNX

Go back to Vericel (VCEL) Misses Q3 EPS by 1c

Vericel Reports Third-Quarter 2015 Financial Results

November 13, 2015 7:29 AM EST

Total Revenues of $11.3 Million Reported for the Third Quarter

Carticel and Epicel Revenues Increase 19% Compared to Third Quarter of 2014

Conference Call Today at 8:00am Eastern Time

CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the quarter ended September 30, 2015. Total revenues for the third quarter were generated primarily from net sales of Carticel® (autologous cultured chondrocytes)... More